8,888 Shares in Sanofi $SNY Acquired by Midwest Trust Co

Midwest Trust Co acquired a new stake in Sanofi (NASDAQ:SNY) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 8,888 shares of the company’s stock, valued at approximately $429,000.

Other hedge funds have also modified their holdings of the company. Capital Analysts LLC increased its holdings in shares of Sanofi by 14.0% in the 1st quarter. Capital Analysts LLC now owns 1,664 shares of the company’s stock valued at $92,000 after acquiring an additional 204 shares during the period. Thomasville National Bank grew its position in Sanofi by 0.3% during the 2nd quarter. Thomasville National Bank now owns 80,440 shares of the company’s stock worth $3,886,000 after purchasing an additional 211 shares during the last quarter. U.S. Capital Wealth Advisors LLC increased its stake in Sanofi by 4.1% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 6,227 shares of the company’s stock valued at $301,000 after purchasing an additional 247 shares during the period. Whipplewood Advisors LLC increased its stake in Sanofi by 18.2% in the second quarter. Whipplewood Advisors LLC now owns 1,606 shares of the company’s stock valued at $78,000 after purchasing an additional 247 shares during the period. Finally, Cetera Trust Company N.A raised its holdings in shares of Sanofi by 4.2% in the second quarter. Cetera Trust Company N.A now owns 6,140 shares of the company’s stock valued at $297,000 after buying an additional 250 shares during the last quarter. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Up 0.4%

Sanofi stock opened at $51.92 on Thursday. The stock’s 50 day moving average price is $48.75 and its 200 day moving average price is $49.45. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The company has a market cap of $127.49 billion, a PE ratio of 12.16, a price-to-earnings-growth ratio of 1.38 and a beta of 0.49. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.06 and a quick ratio of 0.94.

Sanofi (NASDAQ:SNY) last released its earnings results on Friday, October 24th. The company reported $1.70 EPS for the quarter, beating analysts’ consensus estimates of $1.60 by $0.10. Sanofi had a return on equity of 12.70% and a net margin of 21.96%.The company had revenue of $14.53 billion during the quarter, compared to the consensus estimate of $12.62 billion. During the same quarter last year, the company earned $2.25 earnings per share. Sanofi’s quarterly revenue was down 7.5% compared to the same quarter last year. On average, sell-side analysts predict that Sanofi will post 4.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

SNY has been the topic of a number of research reports. JPMorgan Chase & Co. raised Sanofi from a “neutral” rating to an “overweight” rating in a report on Friday, August 8th. Wall Street Zen raised Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Morgan Stanley raised Sanofi from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $56.00 to $58.00 in a report on Monday, September 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.